{
    "code": "02024463",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02024463",
    "time": "2020-02-25 13:22:45",
    "許可證字號": "衛署藥輸字第024463號",
    "註銷狀態": "已註銷",
    "註銷日期": "108\/03\/28",
    "註銷理由": "屆期未申請展延",
    "有效日期": "106\/05\/22",
    "發證日期": "101\/05\/22",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202446300",
    "中文品名": "搏克力濃縮輸注液6毫克\/毫升",
    "英文品名": "Paclitaxin, concentrate for solution for infusion 6mg\/ml",
    "適應症": "晚期卵巢癌、腋下淋巴轉移之乳癌，作為接續含杜薩魯比辛(DOXORUBICIN)在內之輔助化學療法、已使用合併療法(除非有禁忌，至少應包括使用ANTHRACYCLINE抗癌藥)失敗的轉移乳癌、非小細胞肺癌、愛滋病相關卡波西氏肉瘤之第二線療法；與CISPLATIN併用，作為晚期卵巢癌之第一線療法。",
    "劑型": "270注射劑",
    "包裝": "5毫升、16.7毫升小瓶 25毫升、50毫升小瓶 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "藥品分類": "",
    "主製造廠": {
        "限制項目": "02輸　入 1Q不得輸入",
        "申請商名稱": "620102K944  香港商艾維斯有限公司台灣分公司",
        "申請商地址": "台北市中正區忠孝東路二段116號10樓",
        "主製造廠": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000100",
            "成分名稱": "PACLITAXEL",
            "含量描述": "",
            "含量": "6.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "020244630036.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024463&Seq=038&Type=9"
        },
        {
            "title": "020244630007.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024463&Seq=009&Type=8"
        }
    ]
}